# Inflarx NV (IFRX) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/IFRX
## Company Profile
- Ticker: IFRX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: Germany and listed in the U
- Tags: Antibody Drugs, Immunology
## Stock Data
- Close: 2 USD
- Market cap: 319625504.03 USD
- Last updated: 2026-08-11
## Business Overview
### Complement-Targeted Immunology
InflaRx develops anti-inflammatory therapies that inhibit the complement C5a pathway. Its portfolio includes an oral C5a receptor inhibitor and an antibody against C5a.
### Izicopan
Izicopan is an oral C5aR inhibitor designed for differentiated chemistry, metabolic properties and safety. Phase 2a results in hidradenitis suppurativa and chronic spontaneous urticaria support further development in inflammatory and immunologic diseases.
### Hidradenitis Suppurativa Strategy
In hidradenitis suppurativa, izicopan produced reductions in abscesses, nodules, draining tunnels and pain over a short treatment period. InflaRx is preparing a Phase 2b program and discussing the development path with the FDA.
### Vilobelimab and GOHIBIC
Vilobelimab is an anti-C5a antibody authorized or approved under the GOHIBIC brand for selected critically ill COVID-19 patients. The company has also studied it in pyoderma gangrenosum, but further development in that indication would likely require a partner.
## Why The Stock Is Moving

As of Aug 11, 2026, IFRX closed up 2.04% at $2.00. No new same-company headline was identified in the current news window.

## Future Catalysts

- Completion of FDA communications regarding Phase 2b readiness for izicopan in hidradenitis suppurativa.
- Izicopan pharmacokinetic bridging study in China planned during 2026 to enable additional proof-of-concept studies.

## Recent News
- 2026-08-06 11:30 EST — [InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones](https://biopharmsignal.com/news/IFRX/inflarx-reports-second-quarter-2026-results-and-highlights-key-achievements-and--0d4f5d46) — Source: Inflarx NV
- 2026-07-30 11:30 EST — [InflaRx to Report Second Quarter 2026 Results on  August 6, 2026](https://biopharmsignal.com/news/IFRX/inflarx-to-report-second-quarter-2026-results-on-august-6-2026-2e4e70f5) — Source: Inflarx NV
- 2026-06-30 11:30 EST — [InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos](https://biopharmsignal.com/news/IFRX/inflarx-assessing-feasibility-of-broadened-strategy-for-anca-associated-vasculit-7f39d900) — Source: Inflarx NV
- 2026-05-08 12:15 EST — [InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares](https://biopharmsignal.com/news/IFRX/inflarx-announces-closing-of-150-million-underwritten-offering-of-ordinary-share-085761a8) — Source: Inflarx NV
- 2026-05-06 12:30 EST — [InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares](https://biopharmsignal.com/news/IFRX/inflarx-announces-pricing-of-150-million-underwritten-offering-of-ordinary-share-36e34ae6) — Source: Inflarx NV